AKBA up +8.68% percent right now. $AKBA High is at
Post# of 94186
Posted On: 11/11/2014 3:08:53 PM
AKBA up +8.68% percent right now. $AKBA High is at 9.88 and the Low 9.32 with current volume of 147,944.
Recent News posted below.
AKBA Akebia Therapeutics Inc. Recent Headline News
Akebia Announces Poster Presentations at the Upcoming American Society of Nephrology Kidney Week 2014 Annual Meeting
Business Wire - Tue Nov 11, 6:00AM CST
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced that data from the AKB-6548 development program will be presented in two poster sessions at the upcoming American Society of Nephrology (ASN) Kidney Week 2014 annual meeting in Philadelphia, PA from November 11-16, 2014.
AKBA: 10.10 (+1.11)
Nasdaq stocks posting largest percentage decreases
AP - Mon Nov 10, 5:07PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
HYGS: 14.92 (-1.04), KNDI: 15.45 (+0.59), PAAS: 9.74 (+0.57), PAA.TO: 11.01 (+0.57), RPRX: 9.70 (+0.48), REXX: 7.65 (+0.42), HYG.TO: 16.92 (-1.25), AKBA: 10.10 (+1.11), MTEX: 19.55 (-0.22), SHLD: 37.03 (-1.69)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 11:59AM CST
UCP: 11.63 (-0.26), JRJC: 7.46 (+1.02), NAVB: 1.00 (-0.03), SANW: 3.65 (+0.01), PLPM: 1.74 (+0.07), RYN: 26.59 (-2.23), INFU: 2.91 (-0.06), LIOX: 5.41 (-0.13), DY: 28.14 (+0.17), MTZ: 24.83 (-0.10), CGIX: 6.52 (-0.16), MUX: 1.40 (+0.17), OREX: 5.04 (-0.09), URRE: 2.45 (-0.11), ACHN: 12.41 (-0.44), REN: 2.71 (-0.19), MPO: 3.14 (-0.07), AKBA: 10.10 (+1.11), TRX: 1.16 (+0.12), PLNR: 6.65 (-1.03)
Akebia misses by $0.02
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 6:20AM CST
AKBA: 10.10 (+1.11)
Akebia Announces Third Quarter 2014 Financial Results
Business Wire - Mon Nov 10, 6:00AM CST
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced financial results for the third quarter ended September 30, 2014.
AKBA: 10.10 (+1.11)
Akebia to Participate in Upcoming Investor Conferences
Business Wire - Fri Oct 31, 6:00AM CDT
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced that John P. Butler, President and Chief Executive Officer, will participate in two upcoming investor conferences:
AKBA: 10.10 (+1.11)
Akebia getting roughed up
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 2:55PM CDT
AKBA: 10.10 (+1.11)
Akebia renal anemia drug successful in Phase 2
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 6:13AM CDT
AKBA: 10.10 (+1.11)
Akebia Announces Positive Top-Line Results from its Phase 2b Study of AKB-6548 in Non-Dialysis Patients with Anemia Related to Chronic Kidney Disease
Business Wire - Mon Oct 27, 5:30AM CDT
--Company Plans to Initiate Global Phase 3 Registration Studies in 2015
AKBA: 10.10 (+1.11)
Akebia Announces Dosing of First Patient in Phase 2 Study of AKB-6548 in Patients with Anemia Related to Chronic Kidney Disease Undergoing Dialysis
Business Wire - Thu Sep 25, 6:00AM CDT
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on the development of novel, proprietary therapeutics based on hypoxia-inducible factor (HIF) biology and the commercialization of these products for patients with kidney disease, today announced that the first patient has been dosed in a Phase 2 clinical study of AKB-6548 in patients with anemia related to chronic kidney disease (CKD) who are undergoing dialysis. AKB-6548 is being developed as a once-daily, oral therapy with best-in-class potential for the treatment of anemia related to CKD.
AKBA: 10.10 (+1.11)
Concert Pharmaceuticals (CNCE) Soars: Stock Rises 25.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 7:57AM CDT
Concert Pharmaceuticals, Inc. (CNCE) was a big mover last session, as the company saw its shares rise nearly 26% on the day.
LCI: 50.19 (-1.62), AKBA: 10.10 (+1.11), CNCE: 13.20 (-0.17), HPTX: 21.70 (+0.12)
Others Overlooked Akebia Therapeutics (AKBA), Should You Buy It Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 7:45AM CDT
Akebia Therapeutics has been witnessing a positive trend in its current year estimates and possess a favorable Zacks Rank #2(Buy)
AKBA: 10.10 (+1.11)
Akebia Therapeutics Appoints Ronald C. Renaud Jr. to its Board of Directors
Business Wire - Mon Sep 15, 6:15AM CDT
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on the development of novel, proprietary therapeutics based on hypoxia-inducible factor (HIF) biology and the commercialization of these products for patients with kidney disease, today announced that Ronald C. Renaud, Jr., former President, Chief Executive Officer and Director of Idenix Pharmaceuticals, Inc., has been appointed to Akebia's Board of Directors.
AKBA: 10.10 (+1.11), IDIX: 24.50 (+0.05)
Akebia Therapeutics, Inc. (NASDAQ: AKBA) to Ring The NASDAQ Stock Market Opening Bell
GlobeNewswire - Thu Sep 11, 9:06AM CDT
What:
AKBA: 10.10 (+1.11), NDAQ: 44.14 (+0.11)
Can the Uptrend Continue for Akebia (AKBA)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 8:33AM CDT
Can the Uptrend Continue for Akebia (AKBA)?
AKBA: 10.10 (+1.11)
Akebia Announces Second Quarter 2014 Financial Results
Business Wire - Mon Aug 11, 6:00AM CDT
---Strengthens Management Team and Board-
AKBA: 10.10 (+1.11)
Akebia Therapeutics Announces Expansion of Management Team
Business Wire - Wed Aug 06, 6:00AM CDT
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on harnessing the potential of hypoxia-inducible factor (HIF) biology to develop and commercialize novel therapeutics to treat kidney disease, today announced the expansion of its senior management team with three key additions: Brad Maroni, M.D., as Senior Vice President and Chief Medical Officer, Mark De Rosch, Ph.D., as Vice President of Regulatory Affairs and Tamara Dillon as Vice President of Human Resources.
AKBA: 10.10 (+1.11)
Akebia Therapeutics Appoints Michael Clayman, M.D. and Maxine Gowen, Ph.D. to its Board of Directors
Business Wire - Thu Jul 17, 6:00AM CDT
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on harnessing the potential of hypoxia-inducible factor (HIF) biology to develop and commercialize novel therapeutics to treat kidney disease, today announced that Michael D. Clayman, M.D., Chief Executive Officer of Flexion Therapeutics, Inc., and Maxine Gowen, Ph.D., President and Chief Executive Officer of Trevena, Inc., have been appointed to the Company's Board of Directors. In addition, Kim L. Dueholm, Ph.D. will be stepping down from the Board on July 28, 2014, the effective date of Dr. Clayman and Dr. Gowen's appointments.
TRVN: 5.64 (-0.21), FLXN: 18.88 (+0.01), AKBA: 10.10 (+1.11)
Recent News posted below.
AKBA Akebia Therapeutics Inc. Recent Headline News
Akebia Announces Poster Presentations at the Upcoming American Society of Nephrology Kidney Week 2014 Annual Meeting
Business Wire - Tue Nov 11, 6:00AM CST
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced that data from the AKB-6548 development program will be presented in two poster sessions at the upcoming American Society of Nephrology (ASN) Kidney Week 2014 annual meeting in Philadelphia, PA from November 11-16, 2014.
AKBA: 10.10 (+1.11)
Nasdaq stocks posting largest percentage decreases
AP - Mon Nov 10, 5:07PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
HYGS: 14.92 (-1.04), KNDI: 15.45 (+0.59), PAAS: 9.74 (+0.57), PAA.TO: 11.01 (+0.57), RPRX: 9.70 (+0.48), REXX: 7.65 (+0.42), HYG.TO: 16.92 (-1.25), AKBA: 10.10 (+1.11), MTEX: 19.55 (-0.22), SHLD: 37.03 (-1.69)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 11:59AM CST
UCP: 11.63 (-0.26), JRJC: 7.46 (+1.02), NAVB: 1.00 (-0.03), SANW: 3.65 (+0.01), PLPM: 1.74 (+0.07), RYN: 26.59 (-2.23), INFU: 2.91 (-0.06), LIOX: 5.41 (-0.13), DY: 28.14 (+0.17), MTZ: 24.83 (-0.10), CGIX: 6.52 (-0.16), MUX: 1.40 (+0.17), OREX: 5.04 (-0.09), URRE: 2.45 (-0.11), ACHN: 12.41 (-0.44), REN: 2.71 (-0.19), MPO: 3.14 (-0.07), AKBA: 10.10 (+1.11), TRX: 1.16 (+0.12), PLNR: 6.65 (-1.03)
Akebia misses by $0.02
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 6:20AM CST
AKBA: 10.10 (+1.11)
Akebia Announces Third Quarter 2014 Financial Results
Business Wire - Mon Nov 10, 6:00AM CST
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced financial results for the third quarter ended September 30, 2014.
AKBA: 10.10 (+1.11)
Akebia to Participate in Upcoming Investor Conferences
Business Wire - Fri Oct 31, 6:00AM CDT
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced that John P. Butler, President and Chief Executive Officer, will participate in two upcoming investor conferences:
AKBA: 10.10 (+1.11)
Akebia getting roughed up
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 2:55PM CDT
AKBA: 10.10 (+1.11)
Akebia renal anemia drug successful in Phase 2
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 6:13AM CDT
AKBA: 10.10 (+1.11)
Akebia Announces Positive Top-Line Results from its Phase 2b Study of AKB-6548 in Non-Dialysis Patients with Anemia Related to Chronic Kidney Disease
Business Wire - Mon Oct 27, 5:30AM CDT
--Company Plans to Initiate Global Phase 3 Registration Studies in 2015
AKBA: 10.10 (+1.11)
Akebia Announces Dosing of First Patient in Phase 2 Study of AKB-6548 in Patients with Anemia Related to Chronic Kidney Disease Undergoing Dialysis
Business Wire - Thu Sep 25, 6:00AM CDT
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on the development of novel, proprietary therapeutics based on hypoxia-inducible factor (HIF) biology and the commercialization of these products for patients with kidney disease, today announced that the first patient has been dosed in a Phase 2 clinical study of AKB-6548 in patients with anemia related to chronic kidney disease (CKD) who are undergoing dialysis. AKB-6548 is being developed as a once-daily, oral therapy with best-in-class potential for the treatment of anemia related to CKD.
AKBA: 10.10 (+1.11)
Concert Pharmaceuticals (CNCE) Soars: Stock Rises 25.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 7:57AM CDT
Concert Pharmaceuticals, Inc. (CNCE) was a big mover last session, as the company saw its shares rise nearly 26% on the day.
LCI: 50.19 (-1.62), AKBA: 10.10 (+1.11), CNCE: 13.20 (-0.17), HPTX: 21.70 (+0.12)
Others Overlooked Akebia Therapeutics (AKBA), Should You Buy It Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 7:45AM CDT
Akebia Therapeutics has been witnessing a positive trend in its current year estimates and possess a favorable Zacks Rank #2(Buy)
AKBA: 10.10 (+1.11)
Akebia Therapeutics Appoints Ronald C. Renaud Jr. to its Board of Directors
Business Wire - Mon Sep 15, 6:15AM CDT
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on the development of novel, proprietary therapeutics based on hypoxia-inducible factor (HIF) biology and the commercialization of these products for patients with kidney disease, today announced that Ronald C. Renaud, Jr., former President, Chief Executive Officer and Director of Idenix Pharmaceuticals, Inc., has been appointed to Akebia's Board of Directors.
AKBA: 10.10 (+1.11), IDIX: 24.50 (+0.05)
Akebia Therapeutics, Inc. (NASDAQ: AKBA) to Ring The NASDAQ Stock Market Opening Bell
GlobeNewswire - Thu Sep 11, 9:06AM CDT
What:
AKBA: 10.10 (+1.11), NDAQ: 44.14 (+0.11)
Can the Uptrend Continue for Akebia (AKBA)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 18, 8:33AM CDT
Can the Uptrend Continue for Akebia (AKBA)?
AKBA: 10.10 (+1.11)
Akebia Announces Second Quarter 2014 Financial Results
Business Wire - Mon Aug 11, 6:00AM CDT
---Strengthens Management Team and Board-
AKBA: 10.10 (+1.11)
Akebia Therapeutics Announces Expansion of Management Team
Business Wire - Wed Aug 06, 6:00AM CDT
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on harnessing the potential of hypoxia-inducible factor (HIF) biology to develop and commercialize novel therapeutics to treat kidney disease, today announced the expansion of its senior management team with three key additions: Brad Maroni, M.D., as Senior Vice President and Chief Medical Officer, Mark De Rosch, Ph.D., as Vice President of Regulatory Affairs and Tamara Dillon as Vice President of Human Resources.
AKBA: 10.10 (+1.11)
Akebia Therapeutics Appoints Michael Clayman, M.D. and Maxine Gowen, Ph.D. to its Board of Directors
Business Wire - Thu Jul 17, 6:00AM CDT
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on harnessing the potential of hypoxia-inducible factor (HIF) biology to develop and commercialize novel therapeutics to treat kidney disease, today announced that Michael D. Clayman, M.D., Chief Executive Officer of Flexion Therapeutics, Inc., and Maxine Gowen, Ph.D., President and Chief Executive Officer of Trevena, Inc., have been appointed to the Company's Board of Directors. In addition, Kim L. Dueholm, Ph.D. will be stepping down from the Board on July 28, 2014, the effective date of Dr. Clayman and Dr. Gowen's appointments.
TRVN: 5.64 (-0.21), FLXN: 18.88 (+0.01), AKBA: 10.10 (+1.11)
(0)
(0)Scroll down for more posts ▼